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Endometrium is not the primary site of origin
of pelvic high-grade serous carcinoma in
BRCA1 or BRCA2 mutation carriers
Welmoed Reitsma1, Marian JE Mourits1, Geertruida H de Bock2 and Harry Hollema3
1Department of Gynecologic Oncology, University of Groningen, University Medical Center Groningen,
Groningen, The Netherlands; 2Department of Epidemiology, University of Groningen, University Medical
Center Groningen, Groningen, The Netherlands and 3Department of Pathology, University of Groningen,
University Medical Center Groningen, Groningen, The Netherlands
Serous endometrial intraepithelial carcinoma has been proposed to be a potential precursor lesion of pelvic
high-grade serous carcinoma. If true, an increased incidence of uterine papillary serous carcinomas would be
expected in BRCA1 and BRCA2 mutation carriers, who are at high-risk of developing pelvic high-grade serous
carcinoma. This study explored particularly the occurrence of uterine papillary serous carcinoma, as well as
other endometrial cancers, following risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2
germline mutation attending a tertiary multidisciplinary clinic. A consecutive series of women with a BRCA1 or
BRCA2 mutation who had undergone risk-reducing salpingo-oophorectomy without hysterectomy at the
University Medical Center Groningen from January 1996 until March 2012 were followed prospectively. They
were crossed with the histopathology list of endometrial cancer diagnoses reported by the Dutch nationwide
pathology database PALGA. To assess the risk of endometrial cancer, a standardized incidence ratio was
calculated comparing the observed with the expected number of endometrial cancer cases. Overall, 201 BRCA1
and 144 BRCA2 mutation carriers at a median age of 50 years (range, 32–78) were analyzed. After a median
follow-up period of 6 years, after risk-reducing salpingo-oophorectomy, two cases of endometrial cancer were
diagnosed, whereas the expected number was 0.94 cases (standardized incidence ratio 2.13; 95% confidence
interval 0.24–7.69; P¼ 0.27). Both endometrial cancer cases were of the endometrioid histological subtype. We
showed that the incidence of endometrial cancer following risk-reducing salpingo-oophorectomy, especially
uterine papillary serous carcinoma, in women at high-risk of developing pelvic high-grade serous carcinoma is
not increased. On the basis of our data, the hypothesis of serous endometrial intraepithelial carcinoma being an
important precursor lesion of pelvic high-grade serous carcinoma seems unlikely. There is no need to add a
prophylactic hysterectomy to risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
Modern Pathology (2013) 26, 572–578; doi:10.1038/modpathol.2012.169; published online 19 October 2012
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Epithelial ovarian cancer is the fifth leading cause of
cancer-related death in women in developed coun-
tries.1 Although there are many subtypes of ovarian
cancer, serous carcinoma is the most frequently
diagnosed histological type, which corresponds to
75% of all cases and 90% of all deaths due to
ovarian cancer.2,3 Serous carcinomas are even more
common in female BRCA1 and BRCA2 mutation
carriers, who are at an increased risk of developing
ovarian cancer, currently known as pelvic high-
grade serous carcinoma4–6 Although low-grade
serous carcinomas (‘type I tumors’) are known to
develop in a stepwise fashion, often associated with
a serous borderline component,7–9 the cell of origin
of pelvic high-grade serous carcinoma (‘type II
tumors’) remains the subject of debate, despite
extensive clinical, histopathological and fundamen-
tal research. One of the major aspects of this
uncertainty is the precursor lesion responsible for
this disease, as a precursor was never identified in
the ovary itself.10
The first described precursor lesion of pelvic high-
grade serous carcinoma in women with a genetic
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predisposition to ovarian cancer is the tubal intra-
epithelial carcinoma, later designated as noninva-
sive serous tubal intraepithelial carcinomas.11,12
Recently, an alternative lesion was proposed to be
a candidate precursor of pelvic high-grade serous
carcinoma: serous endometrial intraepithelial car-
cinoma, an already established precursor lesion or
early phase of uterine papillary serous carci-
noma.13,14 Serous endometrial intraepithelial carci-
noma can be found near or adjacent to uterine
papillary serous carcinoma in 50–90% of the
cases.15,16 If serous endometrial intraepithelial carci-
noma indeed is an important precursor of pelvic high-
grade serous carcinoma as well, one would expect an
increased frequency of uterine papillary serous
carcinoma in women at increased risk of
developing pelvic high-grade serous carcinoma.
Furthermore, uterine papillary serous carcinoma
shares histopathologic, genetic and clinical
features with pelvic high-grade serous carcinoma,
which raised the hypothesis that uterine papillary
serous carcinoma is a malignancy that might be
associated with BRCA1 and BRCA2 mutations.
This study was undertaken to examine and report
particularly the occurrence of uterine papillary
serous carcinoma, as well as other endometrial
cancers, following risk-reducing salpingo-oophor-
ectomy in women with a BRCA1 or BRCA2 germ line
mutation in a tertiary referral medical center. The
expected number of endometrial cancer cases was
calculated, given the duration of follow-up and




From 1996, clinical and genetic data of women with
a BRCA1 or BRCA2 mutation have been prospec-
tively registered at the Family Cancer Clinic of the
University Medical Center Groningen, in a com-
bined setting by a clinical geneticist, a gynecologic
oncologist and a surgical oncologist.17 Genetic
testing for BRCA mutations is available to women
from hereditary breast and/or ovarian cancer fami-
lies.18 Since 2009, annual gynecologic screening is
not offered anymore because of the proven ineffec-
tiveness19–21 and high-risk women are being
counseled to undergo risk-reducing salpingo-
oophorectomy after childbearing age, from the age
of 35 in BRCA1 and from the age of 40–45 in BRCA2
mutation carriers. In the Netherlands, hysterectomy
is not a part of the surgical protocol of risk-reducing
salpingo-oophorectomy. Follow-up after risk-redu-
cing salpingo-oophorectomy is performed by a
surgical oncologist at the outpatient department of
the Family Cancer Clinic of the University Medical
Center Groningen.22–24
Study Design
Initially, a consecutive series of female BRCA1 and
BRCA2 mutation carriers were enrolled, who under-
went risk-reducing salpingo-oophorectomy (ICD
9-CM code 65.6) at the Department of Gynecology
of the University Medical Center Groningen from
1 January 1996 to 1 March 2012. Excluded were
women who had undergone a hysterectomy before
or at risk-reducing salpingo-oophorectomy. The
outcome of interest was particularly the occurrence
of uterine papillary serous carcinoma, as well as
other endometrial cancers, following risk-reducing
salpingo-oophorectomy in women with a BRCA1 or
BRCA2 mutation. A password-protected database
was used to enter the data. According to the Dutch
clinical practice, no further Institutional Review
Board approval was needed for this study.
Data Collection
Data of the BRCA1 and BRCA2 mutation carriers
who underwent risk-reducing salpingo-oophorect-
omy were retrieved from the registration database
of the Family Cancer Clinic. In addition, genetic,
clinical, histopathological and follow-up data were
obtained from medical records, surgical reports and
pathology reports. To detect women who developed
endometrial cancer, the nationwide pathology data-
base ‘PALGA’ of The Netherlands was used, which
is a national archive containing the abstracts of all
pathology reports in the Netherlands since 1991.25
PALGA is a Dutch acronym and abbreviation for
Pathologisch Anatomisch Landelijk Geautomatiseerd
Archief, the Netherlands Nationwide Computer
Network for Registry of cyto- and histopathology.
Every record in the PALGA database contains date
of diagnosis, and a summary of the report and
diagnostic codes similar to the Systematized
Nomenclature of Medicine (SNOMED)26 classifica-
tion of the College of American Pathologists. From
all BRCA1 and BRCA2 mutation carriers who under-
went risk-reducing salpingo-oophorectomy, follow-
up was checked using the PALGA database on the
presence of any malignancy of the endometrium.
The histological subtype of the endometrial cancer
cases (endometrioid, uterine papillary serous or uterine
clear-cell carcinoma) was recorded.
Statistical Analysis
SPSS 18.0 for Windows (SPSS, Chicago, IL, USA)
was used to perform statistical analysis. Descriptive
values of variables were expressed as frequencies
and percentages for discrete data, and as median
and range for continuous data. Follow-up time was
calculated from the date of risk-reducing salpingo-
oophorectomy to the date of hysterectomy, histo-
pathological diagnosis of endometrial cancer or
date of death, whichever occurred first; the data
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for women who were alive without endometrial
cancer or hysterectomy were censored as the date of
their last assessment at the Family Cancer Clinic,
plus 1 year. The risk of endometrial cancer was
quantified using the standardized incidence ratio, in
which the observed number of endometrial cancers
in our high-risk population was contrasted to the
expected number. The expected number of endo-
metrial cancer cases was calculated on the basis
of the incidence of cancer in the general Dutch
population from the 5-year age-specific rates at large
with adjustment for age and calendar year. Inci-
dence rates were obtained from the Dutch Cancer
Registries. The number of observed cases was
assumed to be Poisson-distributed and 95% con-
fidence intervals were calculated according to the
method of Byar.27 Tests were performed with a two-
sided confidence interval and P values ofo0.05 was
considered statistically significant.
Results
From 1 January 1996 until 1 March 2012, 315 women
with BRCA1 or BRCA2 mutations underwent risk-
reducing salpingo-oophorectomy (without hyster-
ectomy), and were included in this study: 201
BRCA1 (64%) and 114 BRCA2 mutation carriers
(36%) (Table 1, Figure 1). The median age at which
risk-reducing salpingo-oophorectomy was carried
out was 43 years (range, 30–71): BRCA1 mutation
carriers at the age of 42 years (range, 30–71 years)
and BRCA2 carriers at 45 (range, 33–66; Po0.001).
risk-reducing salpingo-oophorectomy was performed
following the diagnosis of primary breast cancer in
38% (N¼ 118) of the women and tamoxifen was ever
used by 6% (N¼ 19) of the women; this concerned
16% of women who previously had breast cancer.
The current median age of the women who were
alive without hysterectomy or endometrial cancer at
the date of their last assessment at the Family Cancer
Clinic was 50 years (range, 32–78; N¼ 298). The
total follow-up time after risk-reducing salpingo-
oophorectomy of all subjects was 2 062 woman
years, with a median follow-up of 6 years per
woman (range, 0–27) (Table 2). Two women (1%)
developed endometrial cancer during the follow-up
period vs 0.94 endometrial cancers expected (stan-
dardized incidence ratio 2.13; 95% confidence
interval 0.24–7.69; P¼ 0.27) (Table 3). Both endo-
metrial cancer cases were endometrioid adenocarci-
nomas. The first endometrial cancer case was in
a 44-year-old BRCA1 mutation carrier who, also
carried Lynch syndrome (MSH-2) and, developed
a FIGO stage IA endometrioid cancer 7 months
following risk-reducing salpingo-oophorectomy.
Although she had been offered a hysterectomy
together with risk-reducing salpingo-oophorectomy
(because of Lynch syndrome), she preferred to wait
until the age of 50. The second case was in a 39-year-
old BRCA2 mutation carrier who developed a FIGO
stage IA endometrioid cancer 66 months following
risk-reducing salpingo-oophorectomy. Her family
was positive for colon and endometrial cancer,
and the tumor showed loss of MSH-6 expression;
however, mutation analysis was negative for Lynch
syndrome. Both women did not use tamoxifen in the
past. After risk-reducing salpingo-oophorectomy,
4 women (all BRCA1 carriers) underwent a hyster-
ectomy (1%) and 11 women were deceased at
the end of the follow-up (4%). Indications for
hysterectomy and causes of death are noted below
Figure 1. None of the BRCA1 or BRCA2 muta-
tion carriers developed uterine papillary serous
carcinoma after risk-reducing salpingo-oophorect-
omy. Moreover, no cases of interval pelvic serous
cancers, also known as primary peritoneal cancer,
were diagnosed after risk-reducing salpingo-
oophorectomy.
Discussion
In this prospectively collected series of women with
a BRCA1 or BRCA2 mutation after risk-reducing
salpingo-oophorectomy, the endometrial cancer
incidence was not increased (standardized inci-
dence ratio 2.13; 95% confidence interval 0.24–
7.69; P¼ 0.27). Strengths of this study are the con-
secutive and uniform series of high-risk women that
were evaluated, availability of genetic, clinical and
follow-up data and long duration of follow-up.
Limitations of our study are the small sample size
and the relatively young age at the end of follow-up.
Data are limited on whether or not women with a
BRCA1 or BRCA2 mutation are at increased risk for
endometrial cancer, especially uterine papillary
serous carcinoma, besides pelvic high-grade serous
carcinoma and breast cancer. Previous studies show
conflicting results. In a series of 199 BRCA1 and
BRCA2 mutation carriers, Levine et al 28 showed
that the lifetime risk of endometrial carcinoma is not
increased in BRCA1 or BRCA2 carriers (odds ratio
0.75; 95% confidence interval 0.24–2.34; P¼ 0.6).









42 (30–71) 45 (33–66) 43 (30–71) o0.00
Previous breast cancer (%)
Yes 86 (43) 32 (28) 118 (38) 0.01
No 115 (57) 82 (72) 197 (63)
Tamoxifen ever used (%)
Yes 12 (6) 7 (6) 19 (6) 0.55
No 155 (77) 93 (82) 248 (79)
Unknown 34 (17) 14 (12) 48 (15)
Abbreviation: RRSO, risk-reducing salpingo-oophorectomy.
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In contrast, the Breast Cancer Linkage Consortium
reported an elevated risk of endometrial cancer in
BRCA1 mutation carriers from North America and
Western Europe (relative risk 2.65; 95% confidence
interval 1.69–4.16; Po0.001), but not in BRCA2
carriers (odds ratio 1.25; 95% confidence interval
0.46–3.37).29,30 Yet, the consortium did not provide
information on previous tamoxifen treatment, and
the histopathological subtype of the endometrial
cancer remained unspecified. Also Beiner et al31
found an increased risk of endometrial cancer in a
prospective series of 857 BRCA mutation carriers
(standardized incidence ratio 5.3; Po0.001); however,
the increased risk was contributed to previous tamo-
xifen treatment (26% of study participants) by the
authors and not to BRCA mutations. Furthermore,
Figure 1 Flow-chart of study participants. Abbreviations: FCC¼Family Cancer Clinic; UMCG¼University Medical Center Groningen;
RRSO¼ risk-reducing salpingo-oophorectomy; HBOC¼hereditary breast and/or ovarian cancer family. *Indications for a hysterectomy
before risk-reducing salpingo-oophorectomy: cervical intraepithelial neoplasia (N¼2, both BRCA1); endometriosis (N¼ 1, BRCA1);
prolapse surgery (N¼ 2, BRCA1 and BRCA2); metrorrhagia because of myomatous uterus (N¼ 1, BRCA2); cervical cancer stage IA1
(N¼1, BRCA1); cervical cancer stage IB1 (N¼ 1, BRCA2); unknown (N¼ 1, BRCA2). The case of hysterectomy at risk-reducing salpingo-
oophorectomy was cervical cancer stage IAI (BRCA1). #Specification of both endometrial cancers: see Table 3. zIndications for a
hysterectomy after risk-reducing salpingo-oophorectomy (N¼4): cervical cancer stage IBI (radical hysterectomy), tubal carcinoma,
ovarian carcinoma, primary peritoneal carcinoma. None of these patients had endometrial cancer or cancer in utero. wCauses of death
after risk-reducing salpingo-oophorectomy (N¼11): peritoneal cancer (N¼1, BRCA1); ovarian cancer (N¼ 1, BRCA1); non-hodgekin
lymphoma (N¼ 1, BRCA1); metastasized breast cancer (N¼4, BRCA1; N¼1, BRCA2); pancreatic cancer (N¼ 1, BRCA2); unknown
(N¼2, BRCA2).
Table 2 Follow-up after RRSO
BRCA1 (N¼201) BRCA2 (N¼114) Total (N¼315) P value











Endometrial cancera 1 (1) 1 (1) 2 (1) 0.59
Hysterectomy after RRSO 4 (2) — (0) 4 (1) 0.30
Deceased at last follow-up 7 (4) 4 (4) 11 (4) 1.00
Abbreviation: RRSO, risk-reducing salpingo-oophorectomy.
aSee Table 3.
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all endometrial cancers were consequently of the
endometrioid subtype, which can be related to
tamoxifen use.31,32 Lavie et al33 studied 51 women
with uterine papillary serous carcinoma and found
8 (16%) women to be BRCA1 or BRCA2 mutation
carriers. However, all patients were Asheknazi Jews
and the high incidence of BRCA carriers among
USPC patients in their series may be related to
population bias Goshen et al34 specifically studied
56 unselected cases of uterine papillary serous
carcinoma, and found that BRCA mutations do not
appear to predispose to uterine papillary serous
carcinoma.
In our study of 315 women with a BRCA1 or
BRCA2 mutation, no cases of uterine papillary serous
carcinoma occurred after risk-reducing salpingo-
oophorectomy during a median follow-up of 6 years
per woman (total of 2 062 women years). Two cases
of endometrioid type endometrial cancer were dia-
gnosed of which one occurred in a woman with
Lynch syndrome (MSH-2), and the other one in a
woman with a positive family history of endometrial
cancer and MSH-6 loss in the tumor. We conclude
that both endometrial cancer cases were attributable
to loss of function of MSH2 and MSH6, and not to
the BRCA mutations.
Given the age distribution of endometrial cancers,
the women in our study population were relatively
young (median, 50 years). However, the age dis-
tribution of the subject population was wide (range,
31–77) and 19% of the subjects were 60 years older
at the time of last follow-up.
Four theories about the possible origin of both
sporadic and hereditary pelvic high-grade serous
carcinoma have been put forth. The first and
conventional theory suggests the ovarian surface
epithelium as the tissue of origin.35,36 However, an
ovarian precursor lesion was never identified.10
Second, the pelvic high-grade serous carcinoma
may also develop from the secondary Mu¨llarian
system, which concerns metaplasia from the
peritoneum; however, the rate of peritoneal cancer
after risk-reducing salpingo-oophorectomy is low
(B1%).37–41
The third and currently most supported theory
appoints the fallopian tube as the tissue of origin of
pelvic high-grade serous carcinoma, least because a
possible precursor lesion has been identified for the
first time.12 Serous tubal intraepithelial carcinomas
have been detected in the fallopian tube as the
earliest morphological manifestation of high-grade
serous carcinoma discovered so far, and are thought
to subsequently spread to the ovary.11,42 Examina-
tion of prophylactically removed ovaries and
fallopian tubes of BRCA mutation carriers has been
associated with serous tubal intraepithelial carci-
noma in 3–12%43–45 and with occult carcinomas in
2–20%, which involve the distal fimbrial fallopian
tube in majority of the cases.46,47 Moreover, identical
TP53 mutations in both serous tubal intraepithelial
carcinomas and concomitant pelvic high-grade serous
carcinoma indicate a clonal relationship between
both, suggesting that the fimbrial end of the tube
may be the ultimate origin for many pelvic high-
grade serous carcinomas.48,49
Recently, a fourth primary site was proposed, sug-
gesting serous endometrial intraepithelial carcino-
ma to be a candidate precursor of pelvic high-grade
serous carcinoma 13. In a case series of nine women,
pelvic serous carcinoma and concurrent serous
endometrial intraepithelial carcinomas were identi-
fied and identical TP53 mutations were found in
six of the cases 50. Originally, serous endometrial
intraepithelial carcinoma has been presumed to be
an early phase of uterine papillary serous carcinoma
that is capable of spreading beyond the uterus.15,16
If serous endometrial intraepithelial carcinoma indeed
is an important precursor of pelvic high-grade serous
carcinoma as well as of uterine papillary serous
carcinoma, an increased frequency of uterine papil-
lary serous carcinoma would be expected in women
at an increased risk of developing pelvic high-grade
serous carcinoma. However, no increased incidence
of uterine papillary serous carcinoma was found in
our series and therefore, the hypothesis of serous
endometrial intraepithelial carcinoma being an im-
portant precursor lesion of pelvic high-grade serous
carcinoma in BRCA1 or BRCA2 mutation carriers
seems unlikely. Nonetheless, if this hypothesis
holds true, a hysterectomy should consequently be
added to risk-reducing salpingo-oophorectomy for
women carrying a BRCA1 or BRCA2 mutation.
Prophylactic hysterectomy does not appear to be
generally indicated in BRCA1 and BRCA2 mutation
carriers, as there is no convincing evidence that there
is an increased risk of endometrial cancer in this
population. Still, in some institutions a hysterectomy
is added to risk-reducing salpingo-oophorectomy in














1 2002, 44 years BRCA1þMSH-2 (Lynch) Yes, bilateral (1995,
2000; no tamoxifen)
2002, 7 months following
RRSO, at 44 years
Stage 1A, grade 1 Adenocarcinoma,
endometrioid type
117 months, AL
2 2004, 33 years BRCA2þLynch neg.
Positive
family history of colon
and endometrial cancer
No 2010, 66 months following
RRSO, at 39 years
Stage 1A, grade 1 Adenocarcinoma,
endometrioid type
90 months, AL
Abbreviations: AL, alive without disease; RRSO, risk-reducing salpingo-oophorectomy.
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order to entirely remove the proximal, intramural
portion of the fallopian tube. Tubal cancer is
typically located in the distal part of the fallopian
tube. A large clinicopathological study of 105 tubal
cancers showed that 92% of the tumor was situated
within the fallopian tube, most often in its distal
two-thirds.51 Furthermore, researchers from the
University of Miami studied 2 632 ovarian cancer
cases and reported that 4.5–14.1% of women
developed ovarian cancer after prior hysterectomy
for non-ovarian conditions.52 Similarly, the American
College of Surgeons studied a larger series of 12 316
ovarian cancer cases and reported that 18.2% of these
women had a previous hysterectomy for benign
disease, with ovarian preservation.53 No clinical
trials have yet been performed to study additional
risk-reduction of tubal cancer by adding a hyste-
rectomy to risk-reducing salpingo-oophorectomy.
Furthermore, the relatively simple laparoscopic
risk-reducing salpingo-oophorectomy would be more
extended and expensive, and might be accompanied
by a higher surgical morbidity, a higher risk of
complications and a longer patient recovery time.54
According to our data, there is no clinical indication
to add a hysterectomy to risk-reducing salpingo-
oophorectomy in women at high-risk of developing
pelvic high-grade serous carcinoma.
In conclusion, over a 16-year period, we did not
find an increased risk of endometrial cancer in
BRCA1 or BRCA2 mutation carriers at high risk
for developing pelvic high-grade serous carcinoma,
attending our tertiary multidisciplinary center.
Taken together, these data do not support the hypo-
thesis of serous endometrial intraepithelial carcino-
ma being an important precursor lesion of pelvic
high-grade serous carcinoma in BRCA1 or BRCA2
mutation carriers and there is no clinical indication
to add hysterectomy to risk-reducing salpingo-
oophorectomy in BRCA1 or BRCA2mutation carriers.
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